Professor of Medicine, University of Chicago Medicine
Hematology
Dr. Richard L. Schilsky, MD
Richard Schilsky works in the field of Hematology. He attended University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10/19 in Research/PrimaryCare. He over the years received 3 awards: "Fellow (FASCO)", "Whos Who in Medicine and Healthcare" and "Super Doctor". Richard L. Schilsky, MD is a published doctor. He has 82 papers published. The most current publication "Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology."
Publications
- Extended RAS Gene Mutation Testing in Metastatic ColoRectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: America...
- Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
- Innovative clinical trials for development of personalized Cancer medicine.
- Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology.
- Clinical Cancer advances 2015: annual report on progress against Cancer from the american society of clinical oncology.
- Generalizability of trial results to elderly Medicare patients with advanced solid Tumors (Alliance 70802).
- Optimizing Dosing of Oncology Drugs.
- Reply to f.e. Vera-badillo et Al.
- Implementing personalized Cancer care.
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes.
- Recommendations for management of patients with neuroendocrine Liver metastases.
- Breaking a vicious cycle.
- Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients.
- Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581.
- Publicly Funded Clinical Trials and the Future of Cancer Care.
- Randomized controlled trials and comparative effectiveness research.
- Targeted therapy for Cancer: asking the right questions.
- Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates.
- Scarcity of vital oncology drugs: finding long-term solutions.
- A genome-wide association study of overall survival in pancreatic Cancer patients treated with gemcitabine in CALGB 80303.
- Role of randomized phase III trials in an era of effective targeted therapies.
- Clinical trials in the era of personalized oncology.
- Using patient-initiated study participation in the development of evidence for personalized Cancer therapy.
- Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues.
- Update in hematology and oncology: evidence published in 2010.
- Tumor heterogeneity as the foundation of personalized Cancer treatment.
- Accrual to Cancer clinical trials in the era of molecular medicine.
- The next phase of chemoprevention research.
- Optimizing collection of adverse event data in Cancer clinical trials supporting supplemental indications.
- Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
- Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic Cancer: phase III trial of the Cancer and Leukemia Group B (CA...
- Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.
- Refocusing the war on Cancer: the critical role of personalized treatment.
- Cyclooxygenase-2 and Cancer treatment: understanding the risk should be worth the reward.
- Toward efficient trials in colorectal Cancer: the ARCAD Clinical Trials Program.
- Data submission standards and evidence requirements.
- Commentary: tackling the challenges of developing targeted therapies for Cancer.
- The impact of the privacy rule on Cancer research: variations in attitudes and application of regulatory standards.
- Personalizing Cancer care: American Society of Clinical Oncology presidential address 2009.
- American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic coloRectal carcinoma to predict respons...
- Clinical Cancer advances 2008: major research advances in Cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
- Join ASCO in Welcoming Dr John Cox As Editor-in-Chief.
- Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Thera...
- IntroDuction: contributions of the cooperative groups.
- American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
- Collaboration between cooperative groups and industry.
- Ethical, scientific, and regulatory perspectives regarding the use of placebos in Cancer clinical trials.
- A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal Cancer hepatic metastases: Cancer...
- Drug safety and drug efficacy: two sides of the same coin.
- The role of cooperative groups in Cancer clinical trials.
- Impact of physical activity on Cancer recurrence and survival in patients with stage III colon Cancer: findings from CALGB 89803.
- A concise history of the Cancer and leukemia group B.
- The Cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
- Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
- Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung Cancer trial participants.
- Progress and promise of FDG-PET imaging for Cancer patient management and oncologic drug development.
- Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in wo...
- Cetuximab in the treatment of colorectal Cancer.
- A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
- A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid Tumors.
- Biomarkers, surrogate end points, and the acceleration of drug development for Cancer prevention and treatment: an update prologue.
- Colorectal adenomas: a prototype for the use of surrogate end points in the development of Cancer prevention drugs.
- Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants.
- Are targeted therapies really targeted?
- Hurry up and wait: is accelerated approval of new Cancer drugs in the best interests of Cancer patients?
- Phase I study of an Oral formulation of ZD9331 administered daily for 28 days.
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-po...
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primar...
- A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of Cancer and leukemia group B 9661.
- Tumor markers as clinical Cancer tests--are we there yet?
- Cooperative group tissue banks as research resources: the Cancer and leukemia group B tissue repositories.
- Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
- End points in Cancer clinical trials and the drug approval process.
- Randomized, open-label, phase III study of a 28-day Oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy ...
- Construct validity of medicare chemotherapy claims: the case of 5FU.
- Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced Cancer.
- Silence is golden: gene hypermethylation and survival in large-cell Lymphoma.
- Highlights from the 2013 WIN Symposium: personalised Cancer therapy from innovation to implementation.
- Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
Schools
University Of ChicagoThe Pritzker School Of Medicine
University Tex
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Fellow (FASCO)
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
University of Chicago Pritzker School of Medicine
Hospital
-
University of Chicago Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Gini F. Fleming, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harvey M. Golomb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy Stock, MD |
|
|
Dr. Suzanne D. Conzen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas F. Gajewski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Olatoyosi Odenike, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Brittany Beach
This Doctor is OpenDoctor Recommended.
|